[The results and prospects for the vaccinal prophylaxis of mumps in Russia]

In recent years the rise of morbidity in epidemic parotitis (EP) has been observed in our country, which determines the development of major outbreaks and further increase in EP morbidity due to the regular accumulation of a considerable number of susceptible persons among the vaccinees. This is mainly caused by low immunogenic potency of live parotitis vaccine produced in Russia and the insufficient content of the virus in a vaccination dose. A definite contribution is also made by the insufficient coverage of the population with vaccination, low efficiency of vaccination made in a single injection and the absence of the quality control of the vaccine in individual regions. Only the complex solution of these problems will lead to the liquidation of EP in the country.